



Press release

UPPSALA, September 6, 2013

Report from Isconova AB's (publ) Extraordinary General Meeting held on September 6, 2013

The Extraordinary General Meeting of Isconova AB (publ), held on 6 September 2013, adopted the following resolutions in accordance with proposals from the majority shareholder Novavax, Inc:*)

The number of members of the board shall be six, with no deputy members of the board.

As new board members for the period extending to the next AGM Stanley C. Erck, Sven Andréasson and James F. Young was elected. Stanley C. Erck was elected Chairman of the Board.

The current board members Peter Wells, Björn Sjöstrand and Russell Greig are proposed to remain in their respective office as board members.

The remuneration to the board of directors is SEK 75,000 to each elected member of the board with the exception of Sven Andréasson and Stanley C. Erck to which it is proposed that no remuneration is paid (since they are employed by Isconova and Novavax, Inc., respectively) and that the remuneration to the chairman of the board receives SEK 175,000, i.e. the same amount as resolved at the AGM 2013, however that the remuneration shall be split between resigning members of the board and new members of the board pro rata in relation to the part of the year (from the AGM 2013 until the AGM 2014) during which each relevant person has acted as board member.

The shareholders adopted revised articles of association entailing that the Company's name is changed from "Isconova AB" to "Novavax AB".

The shareholders further thanked Gunnar Fernström and Bo Håkansson for their services and time with the company.

*) Novavax, Inc. is holding more than 90 % of the shares in Isconova AB.

For more information please contact:

Sven Andréasson, CEO Isconova

Tel: 0701-60 60 60

E-mail: sven.andreasson@isconova.com

Isconova AB (publ) discloses the information provided herein pursuant to the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or NASDAQ OMX First North Rulebook. This information was submitted for publication on 6 September 2013 at 11.30 (CET).

This press release has been published in Swedish and English. In the event of any discrepancy in content between the language versions, the Swedish version shall prevail.

TO THE EDITORS

About Isconova

Isconova AB is a leading international vaccine adjuvant company headquartered in Uppsala, Sweden. With deep knowledge of vaccine systems, Isconova is developing vaccines independently and with partners in both the human and veterinary markets. Isconova is a subsidiary of Novavax, Inc. (NASDAQ "NVAX"). For more information on Isconova: www.isconova.com